In the SUMMIT trial, tirzepatide significantly reduced the risk of death from cardiovascular causes or worsening heart failure events in patients with heart failure with preserved ejection fraction (ejection fraction 50% and above) and obesity (BMI 30 kg/m 2 ), compared with placebo (HR 0.62
While studies have primarily only looked at SGLT-2 in kidney transplant patients, we can hypothesize comparable results among liver transplant recipients
Mutations in AR receptor, AR overexpression, intracrine production, contorted expression of enzymes and cofactors of AR, autonomous activation of AR signaling by cytokines in the absence of androgen ligands, and the presence of multiple splice variants of AR are the main causative agents responsible for the therapeutic failure [12, 13]
What drugmakers are arguing about now is what kind of weight comes off, whether patients are losing fat or muscle, and what other benefits could be gained from these drugs
Thats possible, Low Wang said
Chronic tendinopathies may require 2-3 cycles
